| ¿µ¹® | malignant tumor | ÇÑ±Û | ¾Ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-ÈÇÐÀû-»ý¹°ÇÐÀûÀÎ ¹ß¾Ï ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² ÈÇй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù. |
||
| ¿µ¹® | malignant melanoma | ÇÑ±Û | ¾Ç¼ºÈæ»öÁ¾ |
|---|---|---|---|
| ¼³¸í | ÇǺο¡¼ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁÖ·Î ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇÏ´Â µå¹® º´À¸·Î ÇÇºÎ¿Í ±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼ À¯·¡ÇÏ´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀÎ °ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | solid tumor | ÇÑ±Û | °íÇüÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀÎ »óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. ƯÈ÷ Ç¥ÇÇÁ¶Á÷¿¡¼ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | ulcerating tumor | ÇÑ±Û | ±Ë¾ç¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ Ç¥¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇÏ´Â °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇÏ´Â °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ. |
||
| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| MH | malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam... |
|---|---|
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| MHS | major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m... |
| LP | labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar... |
| SEP | self-evaluation process; sensory-evoked potential; septum; somatosensory evoked potential; sperm ent... |
| LMP | Low Malignant Potential |
|---|---|
| MMMT | Malignant Mixed Mesodermal Tumor |
| MMMT | Malignant mixed Mullerian tumor |
| MRT | Malignant rhabdoid tumor |
| CMM | Cutaneous malignant melanoma |
low blood pressure
| low malignant potential tumour | A neoplasm of the ovary, usually arising in young women, composed of complex epithelial hyperplasia without stromas invasion; may recur if incompletely removed surgically, but is clinically less aggressive than carcinoma. Synonym: low malignant potential tumour. (05 Mar 2000) |
|---|---|
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| back pain, low | Symptoms in the low back can relate to the bony lumbar spine, discs between the vertebrae, ligaments around the spine and discs, spinal cord and nerves, muscles of the low back, internal organs of the pelvis and abdomen, and the skin covering the lumbar area. The low back, or lumbar area, functions in structural support, movement, and protection of certain body tissue. (12 Dec 1998) |
| blood sugar, low | The sugar here is glucose. Low blood glucose constitutes hypoglycaemia. Hypoglycaemia is only significant when it is associated with symptoms. It has many causes including drugs, liver disease, surgical absence of the stomach, pre-diabetes, and rare tumours that release excess insulin. (12 Dec 1998) |
| cardiac output, low | A state of subnormal or depressed cardiac output, usually seen in patients with heart failure secondary to coronary artery, hypertensive, primary myocardial, valvular, or pericardial disease. (12 Dec 1998) |
| very low density lipoprotein | <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats (particularly triglycerides) in the bloodstream. Elevations in very low density lipoprotein in the bloodstream are associated with an increased risk of atherosclerosis and coronary artery disease. Acronym: VLDL (18 Nov 1997) |
| Castellani-Low sign | <clinical sign> A fine tremor of the tongue observed in sleeping sickness. (05 Mar 2000) |
| mean lower low water | <marine biology> The average height of the lower low waters over a 19-year period. For shorter periods of observations, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value. (09 Oct 1997) |
| mean low water | <marine biology> The average height of the low waters over a 19-year period. For shorter periods of observations, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value. All low-water heights are included in the average where the type of tide is either semidiurnal or mixed. Only the lower low-water heights are included in the average where the type of tide is diurnal. So determined, mean low water in the latter case is the same as mean lower low water. (09 Oct 1997) |
| placenta, low | Location of the placenta in the lower part of the uterus (womb) so that the placenta partially or completely covers the cervix. Also known as a placenta previa. (12 Dec 1998) |
| heparin, low-molecular-weight | <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. Pharmacological action: anticoagulant, fibrinolytic agent. (12 Dec 1998) |
| infant, low birth weight | An infant having a birth weight of 2500 gm. (5.5 lb.) or less but infant, very low birth weight is available for infants having a birth weight of 1500 grams (3.3 lb.) or less. (12 Dec 1998) |
| infant, very low birth weight | An infant having a birth weight of 1500 grams (3.3 lb.) or less. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|